Genetic Signatures Limited (ASX: GSS)

Company Profile: Genetic Signatures Limited (ASX: GSS) is in Pharmaceuticals, Biotechnology, and Life Sciences industry. The company mainly operates as a molecular diagnostic company and has developed a wide range of products for the detection of infectious diseases. Some of these products are EasyScreen™ Multiplex Real-Time PCR Pathogen Detection Kits, 3base™ Technology. The EasyScreen products are used to provide hospital and pathology laboratories with the molecular tools. These molecular tools, however, are used for screening a wide array of infectious pathogens in a rapid environment. It was founded in 2001 by Dr. Geoffrey Grigg and was admitted to the Official List of the ASX on 31 March 2015 as a healthcare company.

Top 25 Dividend Stocks report for April

People prefer a dividend stock in their portfolio as it possesses the feature of compounding. Compounding means that the earning which is generated through these dividend stock will get reinvested and will eventually create earnings from earning. More precisely, the dividend generated from these dividend stock will get reinvested to buy another set of a share of the dividend stock which results in giving a higher dividend.

Click here to download your top 25 dividend stocks report!

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report